Aptus Capital Advisors LLC Purchases 3,081 Shares of Marsh & McLennan Companies, Inc. $MRSH

Aptus Capital Advisors LLC boosted its holdings in shares of Marsh & McLennan Companies, Inc. (NYSE:MRSH) by 3.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 97,766 shares of the financial services provider’s stock after purchasing an additional 3,081 shares during the period. Aptus Capital Advisors LLC’s holdings in Marsh & McLennan Companies were worth $19,703,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Longfellow Investment Management Co. LLC raised its holdings in shares of Marsh & McLennan Companies by 25,652.9% during the 3rd quarter. Longfellow Investment Management Co. LLC now owns 4,378 shares of the financial services provider’s stock worth $882,000 after buying an additional 4,361 shares in the last quarter. Barclays PLC grew its position in Marsh & McLennan Companies by 41.7% in the third quarter. Barclays PLC now owns 2,202,372 shares of the financial services provider’s stock valued at $443,844,000 after acquiring an additional 647,987 shares during the last quarter. Cambria Investment Management L.P. bought a new position in shares of Marsh & McLennan Companies in the third quarter worth about $215,000. Insigneo Advisory Services LLC boosted its stake in shares of Marsh & McLennan Companies by 104.0% in the 3rd quarter. Insigneo Advisory Services LLC now owns 2,837 shares of the financial services provider’s stock valued at $572,000 after purchasing an additional 1,446 shares in the last quarter. Finally, Claro Advisors LLC bought a new stake in shares of Marsh & McLennan Companies during the 3rd quarter valued at approximately $224,000. Institutional investors own 87.99% of the company’s stock.

Marsh & McLennan Companies Stock Down 0.0%

NYSE:MRSH opened at $184.91 on Friday. Marsh & McLennan Companies, Inc. has a 52 week low of $170.37 and a 52 week high of $248.00. The firm has a market capitalization of $89.52 billion, a PE ratio of 21.93, a PEG ratio of 2.51 and a beta of 0.74. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.10 and a current ratio of 1.10.

Marsh & McLennan Companies (NYSE:MRSH) last released its earnings results on Thursday, January 29th. The financial services provider reported $2.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.97 by $0.15. Marsh & McLennan Companies had a net margin of 15.42% and a return on equity of 31.60%. The business had revenue of $6.60 billion for the quarter, compared to analyst estimates of $6.52 billion. During the same quarter in the previous year, the business earned $1.87 earnings per share. Marsh & McLennan Companies’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, research analysts forecast that Marsh & McLennan Companies, Inc. will post 9.61 earnings per share for the current year.

Marsh & McLennan Companies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Thursday, April 9th will be given a dividend of $0.90 per share. The ex-dividend date is Thursday, April 9th. This represents a $3.60 annualized dividend and a dividend yield of 1.9%. Marsh & McLennan Companies’s dividend payout ratio is presently 42.70%.

Insider Buying and Selling

In other Marsh & McLennan Companies news, CEO John Q. Doyle sold 16,655 shares of Marsh & McLennan Companies stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $183.30, for a total value of $3,052,861.50. Following the completion of the sale, the chief executive officer directly owned 116,811 shares in the company, valued at approximately $21,411,456.30. The trade was a 12.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.35% of the stock is owned by corporate insiders.

More Marsh & McLennan Companies News

Here are the key news stories impacting Marsh & McLennan Companies this week:

• Positive Sentiment: Recent quarterly results and a new dividend reinforce fundamentals: MMCo reported an earnings beat and revenue growth, and the company declared a $0.90 quarterly dividend (ex-dividend April 9, payable May 15), which supports income-oriented demand. John Doyle Sells 16,655 Shares of Marsh & McLennan Companies (NYSE:MRSH) Stock
• Positive Sentiment: Analyst coverage is mixed-to-favorable: some firms maintained or raised targets (including a Raymond James upgrade) and consensus price targets remain above the current level, which can underpin buying interest. Analysts Set Marsh (NYSE:MRSH) Target Price at $207.38
• Neutral Sentiment: Market write-ups and peer comparisons continue to circulate (analyst notes / comparison pieces) but don’t introduce new company-specific catalysts; they provide context for relative valuation and may influence longer-term flows rather than intraday moves. Comparing Marsh & McLennan Companies (NYSE:MRSH) & Health In Tech (NASDAQ:HIT)
• Negative Sentiment: CEO John Q. Doyle sold 16,655 shares (~$3.05M at ~$183.30), reducing his stake by ~12.5%. Insider selling can weigh on sentiment because it may be interpreted as reduced insider conviction or a signal of liquidity needs. John Doyle Sells 16,655 Shares of Marsh & McLennan Companies (NYSE:MRSH) Stock
• Negative Sentiment: Legal risk: a Bloomberg Law ruling requires Marsh & McLennan to face a fiduciary-breach case tied to health-plan management — this introduces litigation risk and potential remediation costs that can cap valuation multiple until resolved. Marsh & McLennan Must Face Health Plan Fiduciary Breach Case

Analyst Upgrades and Downgrades

Several equities analysts recently commented on MRSH shares. Raymond James Financial raised shares of Marsh & McLennan Companies from an “outperform” rating to a “strong-buy” rating and set a $225.00 price objective for the company in a research note on Tuesday, February 17th. JPMorgan Chase & Co. dropped their price target on Marsh & McLennan Companies from $242.00 to $226.00 and set an “overweight” rating for the company in a research note on Wednesday, January 7th. Cantor Fitzgerald boosted their price objective on Marsh & McLennan Companies from $208.00 to $212.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Keefe, Bruyette & Woods increased their target price on Marsh & McLennan Companies from $205.00 to $206.00 and gave the company a “market perform” rating in a research report on Monday, February 2nd. Finally, Weiss Ratings assumed coverage on Marsh & McLennan Companies in a report on Thursday, January 29th. They set a “hold (c)” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $216.18.

About Marsh & McLennan Companies

Marsh & McLennan Companies (NYSE: MMC) is a global professional services firm headquartered in New York City that provides advice and solutions in the areas of risk, strategy and people. Founded in 1905, the company has grown into a diversified group of businesses focused on insurance brokerage and risk management, reinsurance, human capital and investment consulting, and management consulting. Its long history and scale position it as a prominent adviser to corporations, governments and other institutions seeking to manage risk and optimize human and financial capital.

The firm operates through several well-known subsidiaries and business units that specialize in distinct services.